Most gynecologic cancer patients on medical marijuana reported symptom improvement, especially for nausea | Research

The takeaway

Among 45 gynecologic cancer patients prescribed medical marijuana, 71% reported improvement in at least one symptom, with nausea/vomiting responding better (70%+ improvement) than pain (36% improvement).

Gynecologic oncologists, palliative care providers, cancer patients considering medical marijuana

>70% nausea improvement vs. 36% pain improvement (p=0.02)

What the researchers found

Of 45 patients (89% receiving chemotherapy), 71% reported improvement in at least one symptom after a median 5.2 months of use. Over 70% reported improvement in nausea/vomiting, compared to only 36% reporting pain relief (p=0.02). Side effects were minimal.

Why it matters

Gynecologic cancer patients face severe symptoms from both the disease and chemotherapy. This study provides some of the first data specifically on medical marijuana efficacy in this population, highlighting that nausea may respond better than pain.

The numbers in context

45 patients; 89% receiving chemotherapy; 56% during primary treatment; median use 5.2 months (range 0.6-25.4); 71% improved in at least one symptom; >70% improved nausea/vomiting; 36% improved pain (p=0.02)

How the study worked

Retrospective chart review of 45 gynecologic cancer patients prescribed medical marijuana between May 2016 and February 2019. Electronic medical records queried for formulation, usage patterns, length of use, symptom relief, and side effects.

What this study cannot tell us

Small retrospective sample with no control group. Self-reported outcomes. No standardized assessment tools. Heterogeneous cancer types and treatment regimens. Selection bias in who was prescribed medical marijuana.

How to read the evidence

Small retrospective chart review without controls, providing preliminary descriptive data.

When this study was published

Published in 2021 using 2016-2019 data.

The bigger picture

The differential response between nausea (>70% improvement) and pain (36%) aligns with broader cannabis research showing stronger evidence for nausea than pain, and could help set appropriate expectations for patients and providers.

Questions still open

Why did pain respond so much less than nausea in this population? Would specific cannabinoid formulations improve pain response rates?

Common questions

Did medical marijuana help cancer patients?

Most (71%) reported improvement in at least one symptom. Nausea and vomiting responded best, with over 70% improvement. Pain relief was more modest at 36%.

Were there significant side effects?

The study reported minimal therapy-related side effects, though the retrospective chart review design may have underestimated adverse event reporting.

Read the original research

Medical marijuana utilization in gynecologic cancer patients.

Gynecologic oncology reports, 37, 100820

View on PubMed ↗Publisher’s paper ↗

Citation

Fehniger, Julia; Brodsky, Allison L; Kim, Arum; Pothuri, Bhavana. (2021). Medical marijuana utilization in gynecologic cancer patients.. Gynecologic oncology reports, 37, 100820. https://doi.org/10.1016/j.gore.2021.100820